1 / 8

Age-related Macular Degeneration Therapeutic Pipeline Analysis 2017

The study analysed that the Age-related related macular degeneration therapeutics pipeline comprises of approximately 55 drug candidates, of which five drug candidates are in the Phase III stage, 12 drug candidates are in Phase II stage, 11 drug candidates are in Phase I, 24 drug candidates are in Pre-clinical stage, and there are three drug candidates which are in Discovery stage.

VijayMishra
Download Presentation

Age-related Macular Degeneration Therapeutic Pipeline Analysis 2017

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GLOBAL INDUSTRY INSIGHT: Age-related macular degeneration Therapeutic Pipeline Analysis, 2017 - C linical Trials & Results, Patent, Designation, C ollaboration, and Other Developments

  2. Age-related Macular Degeneration Exhibits Emerging Pipeline with 55 Drug Candidates According to a new research report “ Age-related macular degeneration Therapeutic Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Age-related macular degeneration Therapeutic pipeline currently exhibits a pipeline with 55 drug candidates. Brow se Report Description at: https://www.psmarketresearch.com/market-analysis/age- related-macular-degeneration-therapeutics-pipeline-analysis Age-related macular Degeneration therapeutics pipeline in 2017 The study analysed that the Age-related related macular degenerationtherapeutics pipeline comprises of approximately 55 drug candidates, of which five drug candidates are in the Phase III stage, 12 drug candidates are in Phase II stage, 11 drug candidates are in Phase I, 24 drug candidates are in Pre-clinical stage, and there are three drug candidates which are in Discovery stage. Age-related macular degeneration is a disorder that causes loss of vision in a person due to macula damage; macula is that part of an eye, which helps a person to see, it is made up of millions of light-sensing cells which provide sharp and central vision. The Macula is the most sensitive part of the retina and is located at the back side of the eye. Age-related macular degeneration progresses slowly in an individual and can eventually lead to blindness. The most common symptom of Age-related macular degeneration is blurry vision. Various new therapies and advanced technologies are driving the growth of Age-related macular degeneration therapeutics pipeline. I nsights on pipeline segments As per the findings of the research, around 38.0% of drug candidates of Age-related macular degeneration pipeline are being developed to be administered by intra-vitreal route, 9.0% are being developed to be administered by Subretinal route, 6.0% are being developed to be administered by topical route and 4.0% are being developed to be administered by oral route. The share of drug candidates are being developed to be administered by another route such as, subcutaneous injection, eye drop, Intra-ocular, stand at 5% . The percentage share of undisclosed route of administration is 38.0% . Explore R eport Sample at: https://www.psmarketresearch.com/market-analysis/age-related- macular-degeneration-therapeutics-pipeline-analysis/report-sample New innovating technologies offer development of promising drugs © P&S Market Research. All rights reserved 2

  3. Age-related Macular Degeneration Exhibits Emerging Pipeline with 55 Drug Candidates Many technologies are being developed that can bring the innovative treatment which can control the progression of Age-related macular degeneration. Some of these technologies include but are not limited to, HINGESCREEN technology platform, CrossMab technology platform, Biomimetic technology platform, Vector technology platform and AGTC adeno-associated virus technology platform. Novel therapy for the development of Age-related macular degeneration therapeutics Pipeline There are different novel molecule types that are present in the therapeutic pipeline of Age-related macular degeneration which are useful in the treatment of Age-related macular degeneration. Opregen is a drug under the Phase II stage of development, being developed by Cell Cure Neurosciences. Opregen is a stem cells molecule type useful in the treatment of Age-related macular degeneration. Prodexin is a drug present in Phase II stage of development by Taiwan liposome Company. It is a steroid molecule type which shows efficacy to treat Age-related macular degeneration. Apart from Stem cells and steroids molecule type there are different novel molecules types such as monoclonal antibody, gene therapy, enzymes, vitamins, and peptides which are effective in the treatment of Age-related macular degeneration. Explore Other R elated R eport at: https://www.psmarketresearch.com/industry- report/pharmaceuticals Some of the key players developing drugs for Age-related macular degeneration include Formycon, AG, Allergan Plc, Hoffmann-La Roche, Ophthotech Corporation, Regeneron Pharmaceuticals, Inc., Bayer AG, Santen Inc., Ohr Pharmaceutical Inc., Apellis Pharmaceuticals, Inc., Astellas Pharma Inc., SciFluor Life Sciences, Inc., Stealth BioTherapeutics, Inc., Regenxbio Inc., and Iconic Therapeutics, Inc. Chapter 1. Research Scope and Methodology 1.1 Market Definition 1.2 Market Scope 1.2.1 Global AMD market breakdown by type © P&S Market Research. All rights reserved 3

  4. Age-related Macular Degeneration Exhibits Emerging Pipeline with 55 Drug Candidates 1.2.2 Global AMD market breakdown by drug 1.2.3 Global AMD market breakdown by geography 1.3 Research Methodology and Sources Chapter 2. Executive Summary 2.1 Key Findings 2.2 Research Summary Chapter 3. Market Outlook 3.1 Introduction 3.1.1 Diagnosis of AMD 3.1.2 Stages of AMD 3.1.3 Treatment of AMD 3.1.4 Various drugs for the treatment of AMD 3.1.4.1 Lucentis 3.1.4.2 Eylea 3.1.4.3 Avastin 3.1.4.4 Visudyne 3.2 Trends in the Market 3.2.1 Increasing awareness of AMD 3.3 Factors Driving Growth of the Market and its Impact on Market Forecast 3.3.1 Growing geriatric population 3.3.2 Increasing prevalence of AMD 3.3.3 Increasing prevalence of lifestyle associated diseases 3.3.4 Increasing pipeline drugs for AMD 3.3.5 Increasing healthcare cost 3.3.6 Impact analysis of drivers on market forecast 3.4 Factors Hindering the Growth of the Market and its Impact on Market Forecast © P&S Market Research. All rights reserved 4

  5. Age-related Macular Degeneration Exhibits Emerging Pipeline with 55 Drug Candidates 3.4.1 Increase in off label use 3.4.2 Stringent regulatory requirements 3.4.3 Impact analysis of restraints on market forecast Chapter 4. Drug Approval Process in the U.S. and EU 4.1 Drug approval process in the U.S. 4.2 Drug approval process in the EU Chapter 5. Global Age-related Macular Degeneration Market Size and Forecast (2012 – 2022) 5.1 Global AMD Market, by Type 5.2 Global AMD Market, by Drug 5.3 Global AMD Market, by Region Chapter 6. Global Age-related Macular Degeneration Market, by Type 6.1 Dry AMD Market 6.2 Wet AMD Market Chapter 7. Global Age-related Macular Degeneration Market, by Geography 7.1 North America AMD Market 7.1.1 North America AMD market, by type 7.1.2 North America AMD market, by country 7.2 Europe AMD Market 7.2.1 Europe AMD market, by type 7.2.2 Europe AMD market, by country 7.3 Asia-Pacific AMD Market 7.3.1 Asia-Pacific AMD market, by type 7.3.2 Asia-Pacific AMD market, by country 7.4 Rest of the World (RoW) AMD Market 7.4.1 RoW AMD market, by type Chapter 8. Competitive Positioning Analysis © P&S Market Research. All rights reserved 5

  6. Age-related Macular Degeneration Exhibits Emerging Pipeline with 55 Drug Candidates 8.1 Porter’s Five Forces of Competitive Position Analysis 8.1.1 Bargaining power of buyers 8.1.2 Bargaining power of suppliers 8.1.3 Threat of new entrants 8.1.4 Intensity of rivalry 8.1.5 Threat of substitutes 8.2 Pipeline Analysis of AMD drugs Chapter 9. Company Profiles and Strategic Developments 9.1 Key Company Profiles 9.1.1 Novartis AG 9.1.1.1 Business overview 9.1.1.2 Product and service offerings 9.1.2 F. Hoffmann-La Roche Ltd 9.1.2.1 Business overview 9.1.2.2 Product and service offerings 9.1.3 Bayer AG. 9.1.3.1 Business overview 9.1.3.2 Product and service offerings 9.1.4 Regeneron Pharmaceutical, Inc. 9.1.4.1 Business overview 9.1.4.2 Product and service offerings 9.1.5 Acucela 9.1.5.1 Business overview 9.1.5.2 Product and service offerings 9.1.6 Ophthotech Corporation 9.1.6.1 Business overview © P&S Market Research. All rights reserved 6

  7. Age-related Macular Degeneration Exhibits Emerging Pipeline with 55 Drug Candidates 9.1.6.2 Product and service offerings 9.1.7 Neurotech Pharmaceuticals, Inc. 9.1.7.1 Business overview 9.1.7.2 Product and service offerings 9.1.8 GlaxoSmithKline plc 9.1.8.1 Business overview 9.1.8.2 Product and service offerings 9.1.9 StemCells Inc. 9.1.9.1 Business overview 9.1.9.2 Product and service offerings 9.1.10 Alimera Sciences, Inc. 9.1.10.1 Business overview 9.1.10.2 Product and service offerings 9.2 Strategic Developments in the AMD Market 9.2.1 Collaborations/ partnerships 9.2.2 Product approval/launch 9.2.3 Merger and acquisition 9.2.4 Other developments Chapter 10. Appendix 10.1 List of Abbreviations About P&S Market Research P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals. © P&S Market Research. All rights reserved 7

  8. Age-related Macular Degeneration Exhibits Emerging Pipeline with 55 Drug Candidates As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions. Contact: Kundan Manager – Client Partner 347, 5th Ave. #1402 New York City, NY - 10016 Toll-Free: + 1-888-778-7886 (USA/Canada) Email: enquiry@psmarketresearch.com Web: https://www.psmarketresearch.com © P&S Market Research. All rights reserved 8

More Related